Research & development has been the foundation of Boehringer Ingelheim's success and continues to be the major driver of innovative, new medicines for the treatment of diseases with an unmet therapeutic need. Furthermore, in our constant quest for pharmaceutical innovation we have successful ongoing collaborations and are actively seeking new collaborations with external partners, ranging from academic institutions to biopharmaceutical enterprises and start-up companies.
Research and development activities, with our large research sites in Germany (Biberach), the USA (Ridgefield) and Austria (Vienna), were focused on various therapeutic areas such as:
During the past decade, from 2004 to 2013, Boehringer Ingelheim conducted or sponsored 1,377 studies with approximately one million patients on 119 substances in 98 countries.
More than 7,700 highly qualified people of Boehringer Ingelheim’s over 47,400 employees worldwide work in Research & Development.
In 2013, Boehringer Ingelheim achieved net sales of about 14.1 billion euros. R&D expenditure in Prescription Medicines corresponds to 22.4% of the net sales generated in this business.